NCT06441630View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

PHASE3RecruitingINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Essential Hypertension
Interventions
DRUG

AD-227A

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUG

AD-227B

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUG

AD-227C

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUG

Placebo of AD-227B

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUG

Placebo of AD-227C

Per Oral, 1 Tablet, Once a day for 8 weeks

Trial Locations (1)

Unknown

RECRUITING

Gangnam CHA Medical Center, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY